{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:49:02Z","timestamp":1791402542806,"version":"4.3.3"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Carbonic anhydrase inhibitors (CAIs) reduce macular schisis in patients with X-linked retinoschisis (XLRS). The purpose of this study was to determine if CAIs reduce the incidence of complications from XLRS, including macular atrophy, retinal tears, and retinal detachment (RD), the most common causes of vision loss in patients with XLRS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>For this retrospective interventional case series, a chart review of patients examined at Cincinnati Children\u2019s Hospital Medical Center [CCHMC] and Cincinnati Eye Institute [CEI] between 1\/1\/2015 and 1\/16\/2023 was performed. Male patients were included based on genetically-confirmed <jats:italic>RS1<\/jats:italic> or typical clinical presentation with known family history of XLRS with at least two follow-up visits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-eight patients (56 eyes) with XLRS were included. There were 10 <jats:italic>RS1<\/jats:italic> variants among the 21 genotyped patients. Median age at clinical diagnosis was 10.4\u2009years old (range: 0.4\u201355.7\u2009years) with median follow-up time of 4.7\u2009years (range: 0.2\u201338.3\u2009years). Median presenting Snellen visual acuity was 20\/60 (logMAR 0.48, range: 0.18\u20133). In 26 eyes of 15 patients treated with CAIs, median CST pre-treatment was 416 microns (range: 198\u2013701 microns), and median percentage decrease in CST on treatment was 21.8% (range: 0\u201374.5%) from highest pre-treatment CST. Reduction in CST with CAI use was statistically significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.02), but not logMAR VA (<jats:italic>p<\/jats:italic>\u2009=\u20090.64). There was no significant difference in CST between patients treated with topical vs. oral CAI (<jats:italic>p<\/jats:italic>\u2009=\u20090.95) or between patients with partial or complete CAI adherence (<jats:italic>p<\/jats:italic>\u2009=\u20090.60). Ten eyes of seven patients had an RD requiring surgical intervention. No treated eyes developed new macular atrophy, peripheral retinoschisis, retinal tears, or RD; two eyes on topical CAIs had spontaneous resolution of bullous peripheral retinoschisis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>During the follow-up period, patients taking CAIs reduced macular schisis and did not experience new complications of macular atrophy, retinal tears, or RD. This is a relatively large cohort with long-term follow-up periods for patients with XLRS. Reduced macular schisis may not require perfect adherence with CAIs. A large, prospective, randomized, controlled clinical trial is needed to determine the potential of CAIs to improve visual function, reduce retinoschisis, and prevent RD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1281068","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T13:18:58Z","timestamp":1699276738000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Carbonic anhydrase inhibitors limit complications in X-linked retinoschisis"],"prefix":"10.3389","volume":"10","author":[{"given":"Stephanie","family":"Wey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Brill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Miraldi Utz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780195326147.001.0001","volume-title":"Genetic diseases of the eye","author":"Traboulsi","year":"2012"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/BF00291666","article-title":"DNA linkage analysis of X-linked retinoschisis","volume":"78","author":"Dahl","year":"1988","journal-title":"Hum Genet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.preteyeres.2011.12.002","article-title":"X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms","volume":"31","author":"Molday","year":"2012","journal-title":"Prog Retin Eye Res [Internet]"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ophtha.2021.09.021","article-title":"X-linked retinoschisis: novel clinical observations and genetic spectrum in 340 patients","volume":"129","author":"Hahn","year":"2022","journal-title":"Ophthalmology [Internet]"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.oret.2018.09.006","article-title":"Wide-field swept-source OCT and angiography in X-linked retinoschisis","volume":"3","author":"Han","year":"2019","journal-title":"Ophthalmol Retin [Internet]"},{"key":"ref6","first-page":"29","article-title":"Juvenile hereditary retinoschisis","volume":"89","author":"Ewing","year":"1970","journal-title":"Trans Ophthalmol Soc UK [Internet]"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked Retinoschisis: initial findings from a phase I\/IIa trial by intravitreal delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol Ther [Internet]"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1097\/IAE.0000000000003588","article-title":"Topical carbonic anhydrase inhibitors in the long-term treatment of juvenile X-linked retinoschisis","volume":"42","author":"Schmitt","year":"2022","journal-title":"Retina"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1590\/S0004-27492008000200030","article-title":"Use of topical dorzolamide for patients with X-linked juvenile retinoschisis: case report","volume":"71","author":"de Moura Bastos","year":"2008","journal-title":"Arq Bras Oftalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.2147\/OPTH.S114568","article-title":"Rebound macular edema following oral acetazolamide therapy for juvenile X-linked retinoschisis in an Italian family","volume":"10","author":"Galantuomo","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/01.iae.0000237081.80600.51","article-title":"Use of dorzolamide for patients with X-linked retinoschisis","volume":"26","author":"Apushkin","year":"2006","journal-title":"Retina"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajoc.2017.07.008","article-title":"Treatment of cystic cavities in X-linked juvenile retinoschisis: the first sequential cross-over treatment regimen with dorzolamide","volume":"8","author":"Coussa","year":"2017","journal-title":"Am J Ophthalmol Case Rep [Internet]"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ajo.2008.07.041","article-title":"Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin","volume":"147","author":"Walia","year":"2009","journal-title":"Am J Ophthalmol [Internet]"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/13816810.2013.779383","article-title":"Resolution of mid-peripheral schisis in X-linked retinoschisis with the use of dorzolamide","volume":"35","author":"Collison","year":"2014","journal-title":"Ophthalmic Genet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.4103\/ijo.IJO_2061_19","article-title":"Dramatic response to topical dorzolamide in X-linked retinoschisis","volume":"68","author":"Thangavel","year":"2020","journal-title":"Indian J Ophthalmol [Internet]"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/eye.2011.91","article-title":"X-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype","volume":"25","author":"Khandhadia","year":"2011","journal-title":"Eye [Internet]"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13256-016-0905-8","article-title":"Dramatic regression of macular and peripheral retinoschisis with dorzolamide 2% in X-linked retinoschisis: a case report","volume":"10","author":"Sadaka","year":"2016","journal-title":"J Med Case Rep [Internet]"},{"key":"ref18","first-page":"11","article-title":"Intrafamilial phenotype variability in two male siblings, with X-linked juvenile retinoschisis and dorzolamide treatment effect in the natural history of the disease","volume":"8","author":"Christodoulou","year":"2019","journal-title":"Med Hypothesis, Discov Innov Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/archopht.125.4.571","article-title":"Acetazolamide in the treatment of X-linked retinoschisis maculopathy","volume":"125","author":"Ghajarnia","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1001\/archophthalmol.2010.172","article-title":"Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome","volume":"128","author":"Genead","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/ICB.0000000000000495","article-title":"Structural and functional monitoring of extramacular cystoid spaces in a case of X-linked retinoschisis treated with acetazolamide","volume":"12","author":"Collison","year":"2018","journal-title":"Retin Cases Br Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/09286586.2017.1339809","article-title":"Evaluation of approaches to analyzing continuous correlated eye data when sample size is small","volume":"25","author":"Huang","year":"2018","journal-title":"Ophthalmic Epidemiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/eye.2015.3","article-title":"The Royal College of ophthalmologists\u2019 National Ophthalmology Database study of cataract surgery: report 1, visual outcomes and complications","volume":"29","author":"Day","year":"2015","journal-title":"Eye"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.ophtha.2007.05.047","article-title":"Resolution of retinoschisis after vitreous surgery in X-linked retinoschisis","volume":"115","author":"Ikeda","year":"2008","journal-title":"Ophthalmology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/IAE.0b013e3181e587f9","article-title":"The use of carbonic anhydrase inhibitors in the retreatment of cystic macular lesions in retinitis pigmentosa and X-linked retinoschisis","volume":"31","author":"Thobani","year":"2011","journal-title":"Retina"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1136\/bjophthalmol-2016-310110","article-title":"Peripheral fundus findings in X-linked retinoschisis","volume":"101","author":"Fahim","year":"2017","journal-title":"Br J Ophthalmol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1281068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T13:19:02Z","timestamp":1699276742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1281068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":26,"alternative-id":["10.3389\/fmed.2023.1281068"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1281068","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"article-number":"1281068"}}